Eko Analysis Software vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Eko Analysis Software focuses on the early detection of heart murmurs and atrial fibrillation using digital stethoscope data and ECGs. In contrast, EchoGo Amyloidosis is an AI-powered screening tool specifically designed to identify cardiac amyloidosis from echocardiogram video clips. While both are FDA-cleared AI solutions in cardiology, they address different cardiovascular conditions with distinct input modalities, making them complementary tools rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Eko Analysis Software is designed for the early detection of cardiovascular diseases such as heart murmurs and atrial fibrillation, as well as identifying normal sinus rhythm. EchoGo Amyloidosis, conversely, is specifically an FDA-cleared AI-powered screening tool for the early detection of cardiac amyloidosis.
Eko Analysis Software integrates with Eko's digital stethoscopes and mobile app, analyzing heart sounds and ECGs. EchoGo Amyloidosis analyzes echocardiogram video clips and is designed for seamless integration with existing clinical IT infrastructure, including PACS, DICOM, and HL7.
Eko Analysis Software provides FDA-cleared AI for heart murmur detection (with 85.6% sensitivity and 84.4% specificity for significant valvular heart disease in adults, and 90.2% sensitivity and 90.6% specificity for structural murmurs in adults) and AFib detection (with 98.9% sensitivity and 96.9% specificity). EchoGo Amyloidosis identifies suspected cardiac amyloidosis with a diagnostic output of 'suggestive' or 'not suggestive' of CA, demonstrating high diagnostic accuracy with 85% sensitivity and 93% specificity, and consistent performance across CA subtypes.
Eko Analysis Software is designed for a broader range of specialties including Cardiology, Emergency Medicine, and Internal Medicine. EchoGo Amyloidosis is primarily targeted towards Cardiology.
Eko Analysis Software requires integration with Eko's digital stethoscopes and the Eko mobile app, which is compatible with various iOS and Android devices supporting Bluetooth. EchoGo Amyloidosis is a software-only solution that analyzes existing echocardiogram video clips and does not require additional hardware or software installations at the clinical site.